Price recently closed above the POC line (YTD) and the 10 ema recently crossed the 20 ema. MACD crossed and the RSI is still pretty cool. Looking for it to break its descending trend line. Targeting: 1.96, 2.08, 2.26
I like the several days of consolidation at the 200MA in addition to the bullish pin bar yesterday. The MACD is crossing and the price is still bellow the POC line YTD. I think this is headed into an uptrend. target $1.78, $1.96, $2.25
SVRA Swing trade Idea : Entry :$1.62 Stop :$1.56 PT :$1.92 R/R-1/5 Possible PT date -May 13th P.S. For entreatment purposes only ,not financial advice .
Finding nice support on 200 day most of my analysis focuses on this blue line because it acts as Great support or great resistance. This one is not a bad buy at all. Keep your eyes peeled on it.
Contextual immersion trading strategy idea. Savara Inc. operates as an orphan lung disease company. The demand for shares of the company looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $1,77; stop-loss — $1,54. Information about take-profits will be later. Do not...
Sector: Health Technology Industry: Biotechnology Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April...
The price took out 5 fibonacci levels (.61, .78, 1, 1.61, 2.61) yesterday with the candle gapping up big. It managed to break thru the descending weekly trend line to close just under the .78 level. Also the MACD is freshly crossed and the RSI is still cool especially considering the monster candle yesterday. I think this chart looks bullish AF and Im looking...
Savara Inc. operates as an orphan lung disease company.
Savara Announces Pricing of Public Offering of Common Stock $SVRA today announced the pricing of an underwritten public offering of 45,785,828 shares of its common stock at a price to the public of $1.45 per share. As a component of the offering, in lieu of shares of common stock, Savara offered to certain existing investors pre-funded warrants to purchase an...
It just started a stronger bullish trend as it bounced prior to the previous trend support line. It's staying well above the EMA 30 and has bounced off the RSI support. The last two moves above the support went above 70 and we are assuming this will happen again. Taking this one to the 2s.
touch the resistance and have the potential to rise.
Uptrend has acted as support Severe downtrend has been broken 7712 ma's looking as support Need a increase in volume
Investors in Savara Inc. need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2020 $5.00 Call had some of the highest implied volatility of all equity options today. Source Zacks Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of...
Savara continues to rise afterhours in response to its announcement that the FDA has granted Breakthrough Therapy Designation (BTD) for Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP). The last 45 mins of trading today seen huge buying and...
Savara (NASDAQ:SVRA) is up 96% premarket in response to its announcement that the FDA has granted Breakthrough Therapy Designation (BTD) for Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP). Breakthrough Therapy status provides for more...
Strong breakout reaching to next resistance. Lets see it breaks 10.35 or not.